Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$91.83

-0.29 (-0.31%)

, ALNY

Alnylam

$100.76

0.01 (0.01%)

04:55
04/15/18
04/15
04:55
04/15/18
04:55

European Association for the Study of the Liver to hold a conference

53rd Annual International Liver Congress is being held in Paris, France on April 11-15.

ABBV

AbbVie

$91.83

-0.29 (-0.31%)

ALNY

Alnylam

$100.76

0.01 (0.01%)

BAYRY

Bayer

$30.39

0.03 (0.10%)

GILD

Gilead

$75.22

-0.07 (-0.09%)

CLSN

Celsion

$2.29

-0.08 (-3.38%)

BMY

Bristol-Myers

$58.65

-0.19 (-0.32%)

ICPT

Intercept

$73.07

2.28 (3.22%)

ALXN

Alexion

$111.38

0.09 (0.08%)

BAX

Baxter

$65.72

-0.05 (-0.08%)

GOLD

Randgold

$82.26

1.49 (1.84%)

BRG

Bluerock Residential

$8.72

0.08 (0.93%)

CANF

Can-Fite BioPharma

$1.45

(0.00%)

SBPH

Spring Bank Pharmaceuticals

$13.99

0.02 (0.14%)

MNOV

MediciNova

$12.57

-0.66 (-4.99%)

ENTA

Enanta

$85.98

1.24 (1.46%)

ABUS

Arbutus Biopharma

$5.20

0.1 (1.96%)

CTRV

ContraVir Pharmaceuticals

$0.30

0.0197 (7.03%)

GALT

Galectin Therapeutics

$3.95

-0.32 (-7.49%)

NVO

Novo Nordisk

$49.15

-0.82 (-1.64%)

OSUR

OraSure

$16.80

-0.27 (-1.58%)

ONVO

Organovo

$1.01

-0.04 (-3.81%)

SIEGY

Siemens

$64.65

-0.015 (-0.02%)

VTL

Vital Therapies

$5.90

0.1 (1.72%)

FMS

Fresenius Medical

$50.86

-0.01 (-0.02%)

  • 16

    Apr

  • 17

    Apr

  • 20

    Apr

  • 20

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 03

    May

  • 08

    May

  • 08

    May

  • 18

    May

  • 21

    May

  • 22

    May

  • 30

    May

  • 05

    Jun

  • 10

    Jul

  • 11

    Aug

ABBV AbbVie
$91.83

-0.29 (-0.31%)

04/10/18
PIPR
04/10/18
NO CHANGE
PIPR
Overweight
Piper Jaffray remains bullish on AbbVie, Neurocrine
Piper Jaffray analyst Christopher Raymond reiterated an Overweight rating on AbbVie (ABBV) and Neurocrine (NBIX) shares following this morning's news that the PDUFA date for elagolix for endometriosis will be extended by three months to Q3, as FDA requires extended time to review the results of liver function tests as part of the NDA. For the analyst, the news comes as a bit of a "head-scratcher." Nonetheless, Raymond fully expects Q3 approval.
04/05/18
LEHM
04/05/18
NO CHANGE
LEHM
Barclays upgrades Merck, downgrades Biogen and Pfizer in sector reassessment
Barclays analyst Geoff Meacham made some rating changes while reassessing the Biopharmaceutical sector. Biopharma sentiment has been negative since the start of 2018, despite a modest pick-up in deals and diminished rhetoric on drug pricing, Meacham tells investors in a research note titled "U.S. Biopharmaceuticals: Where to from here?" The analyst believes "more transformative" acquisitions, "clean" Phase 3 wins, and even a relatively strong Q1 earnings season could help "re-rate the sector" and get investors more engaged in the group. Ahead of the Q1 earnings season, Meacham upgraded Merck (MRK) to Overweight from Equal Weight and downgraded to Equal Weight from Overweight shares of Biogen (BIIB), Pfizer (PFE), Biohaven Pharmaceutical (BHVN) and Myovant Sciences (MYOV). The analyst also lowered his price target for Equal Weight-rated AbbVie (ABBV) to $102 from $120, for Equal Weight-rated Amgen (AMGN) to $180 from $180, for Overweight-rated Prothena (PRTA) to $50 from $70 and for Overweight-rated Incyte (INCY) to $135 from $165.
04/06/18
GSCO
04/06/18
NO CHANGE
Target $135
GSCO
Buy
AbbVie management remains confident in stem platform, says Goldman Sachs
Goldman Sachs analyst Jami Rubin kept her Buy rating and $135 price target on AbbVie, saying that in her latest investor meetings with the company, the management was "stunned" by the magnitude of market cap lost after the topline results of TRINITY on March 22nd. Despite the disappointing trial data, Rubin says that AbbVie management remains confident in its stem platform as its "single agent activity and clean safety profile" validate the therapy. Rubin also believes that the market overreacted, wrongly interpreting the FDA decision by removing the entire Rova-T and stem platform opportunity from AbbVie's valuation model.
04/10/18
BARD
04/10/18
NO CHANGE
Target $84
BARD
Outperform
Neurocrine PDUFA delay 'shock' creates buying opportunity, says Baird
Baird analyst Brian Skorney noted that AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced that the PDUFA date for elagolix in endometriosis-associated pain has been extended three months. While "a bit of a shock," Skorney does not think there has been "any hint of a liver signal for elagolix, to date," and the delay is driven more by an overabundance of caution at the FDA amid its simultaneous review of Esmya, where cases of liver failure have been seen. He recommends using the dip in Neurocrine as a buying opportunity and keeps an Outperform rating and $84 price target on the stock.
ALNY Alnylam
$100.76

0.01 (0.01%)

03/29/18
PIPR
03/29/18
NO CHANGE
Target $182
PIPR
Overweight
Piper says Pfizer's tafamidis poses minimal threat to Alnylam's patisiran
Piper Jaffray analyst Edward Tenthoff attributes weakness in shares of Alnylam (ALNY) to Pfizer (PFE) having reported that tafamidis achieved a significant reduction in all-cause mortality and frequency of cardiovascular-related hospitalizations vs. placebo at 30 months in a trial of ATTR cardiomyopathy patients. However, he would be a buyer of Alnylam amid the pullback, as he sees a minimal competitive threat, contending that patisiran's mechanism of mRNA knockdown is more potent than tafamidis' stabilization. The analyst, who expects patisiran to receive FDA approval broadly in ATTR amyloidosis polyneuropathy and cardiomyopathy by its PDUFA date of August 11, maintains an Overweight rating and $182 price target on Alnylam.
04/03/18
JMPS
04/03/18
NO CHANGE
Target $207
JMPS
Outperform
JMP Securities says Alnylam selloff an 'extreme overreaction' to competitor data
After speaking to Alnylam (ALNY) management about competitor Pfizer's (PFE) positive top-line trial results for tafamidis in patients with transthyretin cardiomyopathy, JMP Securities analyst Michael King said Alnylam believes patisiran has a superior competitive profile compared to tafamidis in patients with hATTR-FAP. He views the selloff in Alnylam shares as "an extreme overreaction" to the presence of a competitor, reminding investors of recent International Symposium on Amyloidosis data that he said suggest that ALN-TTRsc02 will be well positioned with respect to tafamidis. King reiterates his Outperform rating and $207 price target on Alnylam.
04/02/18
JEFF
04/02/18
NO CHANGE
JEFF
Buy
Alnylam weakness on Pfizer data a buying opportunity, says Jefferies
Jefferies analyst Maury Raycroft noted that Alnylam (ALNY) fell by over 8% on Thursday after Pfizer (PFE) announced that the phase 3 ATTR-ACT trial assessing tafamidis in TTR-CM met its primary endpoint and that Alnylam shares are trailing the iShares Nasdaq Biotechnology Index (IBB) again today. While he thinks the tafamidis data provide important clinical outcome results that support the need for treatment and benefit in TTR-CM, he also continues to believe the benefits of knocking down/depleting TTR in earlier-stage patients, as Alnylam's patisiran is meant to do, will lead to better objective improvements, Raycroft tells investors. The analyst, who recommends investors buy Alnylam amid the weakness, keeps a Buy rating on the stock.
03/28/18
EVER
03/28/18
INITIATION
Target $143
EVER
In Line
Alnylam initiated with an In Line at Evercore ISI
Evercore ISI started Alnylam Pharmaceuticals with an In Line rating and $143 price target.
BAYRY Bayer
$30.39

0.03 (0.10%)

11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
04/10/18
BMOC
04/10/18
DOWNGRADE
Target $128
BMOC
Market Perform
Monsanto downgraded to Market Perform at BMO Capital on Bayer deal prospects
As reported earlier, BMO Capital analyst Joel Jackson downgraded Monsanto (MON) to Market Perform from Outperform while keeping his $128 price target. Jackson cites the rising likelihood of the acquisition by Bayer (BAYRY) after yesterday's reports of approval of the merger by the U.S. Department of Justice. The analyst notes that since the stock price is now so close to Bayer's takeout price, the isn't "sufficient spread" to support a more bullish rating. In the event of a breakdown of the deal, Jackson sees downside support for the stock around $110 per share.
12/29/17
JPMS
12/29/17
NO CHANGE
JPMS
Roche added to Analyst Focus List at JPMorgan
JPMorgan analyst Richard Vosser added Roche (RHHBY) to his firm's Analyst Focus List and keeps an Overweight rating on the shares with a SFR 300 price target. The analyst sees Roche as having the most significant earnings upside potential of any of the European large cap pharma stocks in 2018. He believes the potential of the company's pipeline is being underappreciated at current share levels. His top picks for 2018 are Roche and Bayer (BAYRY).
12/28/17
ARGS
12/28/17
NO CHANGE
Target $470
ARGS
Buy
Regeneron price target lowered to $470 from $540 at Argus
Argus analyst Jasper Hellweg lowered his price target on Regeneron (REGN) to $470 to reflect some of the recent weakness in the stock, but keeps his Buy rating. Hellweg says that while the company's growth has slowed in recent years, it continues to benefit from sales of Eylea, collaboration agreements with Sanofi (SNY) and Bayer (BAYRY) as well as a strong new product pipeline.
GILD Gilead
$75.22

-0.07 (-0.09%)

03/21/18
MSCO
03/21/18
NO CHANGE
Target $209
MSCO
Equal Weight
Bluebird Bio price target to $209 from $152 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Bluebird Bio (BLUE) to $209 from $152, stating that he now expects BCMA therapies to take 50% of the third line market by 2030 and noting that bb2121 has 50% market share there. The new assumptions increase his peak sales forecast to about $2.6B from about $1B, he pointed out. However, Harrison keeps an Equal Weight rating on Bluebird, stating that he would expect new data to be available at ASCO in June, but would also expect to see competitor data potentially from Celgene's (CELG) Juno, Gilead's (GILD) Kite, Johnson & Johnson's (JNJ) Nanjing Legend and others.
03/07/18
LEHM
03/07/18
NO CHANGE
Target $59
LEHM
Overweight
Crispr Therapeutics price target raised to $59 from $29 at Barclays
Barclays analyst Gena Wang raised her price target for Crispr Therapeutics (CRSP) to $59 citing the company's technology platform and pipeline value. Several recent events, including the acquisitions of Kite and Juno and Sangamo (SGMO) collaboration with Gilead (GILD), validated the value of cell therapy and the potential of gene-editing technologies to serve as a powerful tool in developing next-generation products, Wang tells investors in a research note. She sees "strong upside potential" in Crispr shares and keeps an Overweight rating on the name.
03/06/18
LEHM
03/06/18
NO CHANGE
Target $95
LEHM
Overweight
Gilead target raised to $95 on favorable doctor survey at Barclays
Barclays analyst Geoff Meacham raised his price target for Gilead Sciences to $95 from $90 after his doctor surgery to assess the outlook for the company's HIV franchise was more favorable than expected. The survey shows stronger than expected support for Biktarvy, Meacham tells investors in a research note. Gilead's HIV franchise will "be the bridge until the next leg of growth from CAR-T and the pipeline kicks in," the analyst tells investors in a research note. He keeps an Overweight rating on Gilead.
02/23/18
FBCO
02/23/18
NO CHANGE
Target $80
FBCO
Neutral
Gilead's near-term launches 'intact' after CCO retirement, says Credit Suisse
Credit Suisse analyst Alethia Young told investors in a research note that she is not concerned about the departure of Gilead Sciences' Chief Commercial Officer Jim Myers after speaking with the company's management. She said that she is "confident" in her estimates around the recent launch for Bictarvy and Yescarta, noting that Myers' departure "has nothing to do" with a performance issue or disagreement, adding that Myers had taken a leave of absence earlier in the year due to family matters. She also noted that the company has had turnover in the CCO role with "limited' disruption. Young has a Neutral rating on Gilead shares.
CLSN Celsion
$2.29

-0.08 (-3.38%)

10/05/17
MAXM
10/05/17
UPGRADE
MAXM
Buy
Celsion upgraded on improved financial outlook at Maxim
As noted earlier, Maxim upgraded Celsion to Buy from Hold. Analyst Jason McCarthy says the changes to the company's agreement with warrant holders, enabling the warrants to be exercised immediately following a rally in the stock, have removed the financial overhang on the company. The analyst remains upbeat on the outlook for the company's ThermoDox product. Target $7.
10/05/17
10/05/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Microsoft (MSFT) upgraded to Buy from Hold at Canaccord with analyst Richard Davis saying investors are underestimating the "virtuous cycles" of Microsoft's four "compelling" growth drivers, namely Office Productivity, Gaming, Marketing, and Azure's Platform as a Service. 2. Biogen (BIIB) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Matthew Harrison saying the base business is underappreciated and Ocrevus share loss is slower than expected. 3. Sherwin-Williams (SHW) upgraded to Buy from Underperform at BofA/Merrill with analyst Steve Byrne saying the company announced a 3%-5% price increase on Tuesday and detailed plans to expand PF EBITDA margin to 19%-21% in 2020 from 17% in 2016. 4. BB&T (BBT) upgraded to Overweight from Equal Weight at Stephens with analyst Terry McEvoy noting that it has been the worst performing Super Regional bank in 2017 and he recommends taking advantage of that underperformance as he expects it to produce among the highest returns in the group going forward. 5. Celsion (CLSN) upgraded on improved financial outlook at Maxim with analyst Jason McCarthy saying the changes to the company's agreement with warrant holders, enabling the warrants to be exercised immediately following a rally in the stock, have removed the financial overhang on the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/20/17
OPCO
11/20/17
INITIATION
Target $9
OPCO
Outperform
Celsion initiated with an Outperform at Oppenheimer
Oppenheimer initiated Celsion with an Outperform and $9 price target.
11/21/17
11/21/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Comcast (CMCSA) initiated with a Buy at Buckingham. 2. Celsion (CLSN) initiated with an Outperform at Oppenheimer. 3. Planet Fitness (PLNT) initiated with a Buy at DA Davidson on growth prospects. 4. Square (SQ) initiated with a Market Perform at Wells Fargo. 5. ForeScout (FSCT) was initiated with an Overweight at JPMorgan and KeyBanc, a Buy at BofA/Merrill, an Equal Weight at Morgan Stanley, and a Neutral at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BMY Bristol-Myers
$58.65

-0.19 (-0.32%)

04/12/18
SBSH
04/12/18
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $78 at Citi
Citi analyst Andrew Baum lowered his price target for Bristol-Myers Squibb (BMY) to $70 after Pfizer (PFE) management made clear to him that they had no interest in acquiring Bristol without transformational data or a de-rating in the shares. The analyst removed the $8 per share risk adjusted M&A premium from his Bristol-Myers target price. He views his new price target as conservative, however, and keeps a Buy rating on the name.
04/12/18
SBSH
04/12/18
NO CHANGE
SBSH
Sell
Pfizer has no interest in acquiring Bristol-Myers right now, says Citi
Citi analyst Andrew Baum says Pfizer's (PFE) CEO made it clear to him that the company has no interest in acquiring Bristol-Myers Squibb (BMY) in the absence of transformational data or a de-rating in the shares. Pfizer has high conviction in its current pipeline and believes that the return on investment is considerably higher than high risk transformational deals, particularly in the immuno-oncology space, Baum tells investors in a research note. The analyst expects Pfizer will meaningfully increase its current share repurchase program from the current $5B-$6B per annum to offset the earnings dilution from higher anticipated R&D investment to monetize its current pipeline. Baum keeps a Sell rating on Pfizer and continues to prefer shares of Merck (MRK), Bristol and Eli Lilly (LLY) in the U.S. The analyst lowered his price target for Bristol shares to $70 from $78 with Pfizer backing away from a potential takeover. He keeps a Buy rating on the shares, however.
04/09/18
HCWC
04/09/18
NO CHANGE
Target $125
HCWC
Buy
Nektar data 'more robust' than Incyte's, says H.C. Wainwright
The failure of Incyte (INCY) and Merck's (MRK) Phase 3 study negatively impacted trading in Nektar Therapeutics (NKTR) shares on Friday, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis." At this year's American Society of Clinical Oncology meeting, the analyst expects Nektar and partner Bristol-Myers Squibb (BMY) to unveil data from at least 40 advanced melanoma patients "supported by in-depth biomarker characterization to comprehensively ascertain the rationale of combining NKTR-214 with Opdivo." The rationale for combining NKTR-214 with Opdivo is "more robust" than epacadostat plus Keytruda, the analyst contends. Further, he believes data generated by the NKTR-214 plus Opdivo combination is "unambiguous." Chattopadhyay reiterates a Buy rating on Nektar shares with a $125 price target.
04/06/18
MZHO
04/06/18
NO CHANGE
Target $103
MZHO
Buy
Mizuho says failure of Incyte's epacadostat ups chances of Nektar takeover
Mizuho analyst Difei Yang raised her price target on Nektar Therapeutics (NKTR) to $103 from $89 after Incyte (INCY) announced this morning the failure of epacadostat in combination with Merck's (MRK) Keytruda in a phase 3 study in melanoma patients. Recent clinical data presented by Nektar reinforced her view of NKTR-214 as one of the most impressive combo agent for checkpoint inhibitors, said Yang, who believes that the failure of epacadostat raises the possibility of a takeout by Bristol-Myers (BMY) in the coming months. She maintains a Buy rating on Nektar shares, which are down 8.5% to $92.75 in afternoon trading.
ICPT Intercept
$73.07

2.28 (3.22%)

02/13/18
WELS
02/13/18
NO CHANGE
Target $57
WELS
Market Perform
Intercept price target lowered to $57 from $62 at Wells Fargo
Wells Fargo analyst Jim Birchenough lowered his price target for Intercept to $57 from $62 following his most recent review of the FDA AERS Safety Database for marketed bile acid analog OCALIVA, and significant increase in patient deaths in Q4. While Intercept has highlighted an independent safety review of post-marketing safety events cited in a September, 2017 FDA Drug Safety Communication, the analyst believes that significant increase in patient deaths in Q4 is concerning and the rate is above that predicted for the approved OCALIVA patient population by his estimate. Birchenough reiterates a Market Perform rating on the shares.
03/28/18
LEER
03/28/18
NO CHANGE
Target $16
LEER
Outperform
More differentiating data at EASL can continue CymaBay momentum, says Leerink
Leerink analyst Joseph Schwartz expects a 6-month Phase 2 study update for CymaBay's (CBAY) seladelpar in primary biliary cholangitis to be reported at the International Liver Congress. The analyst notes CymaBay stock has enjoyed strong momentum since the preliminary 12-week data and he remains optimistic that seladelpar's profile will continue to look differentiated from Intercept's (ICPT) Ocaliva when it comes to safety/tolerability and efficacy in the second-line PBC treatment setting. The analyst reiterates an Outperform rating and $16 price target on CymaBay's shares.
02/12/18
DBAB
02/12/18
NO CHANGE
Target $103
DBAB
Buy
Intercept study initiation a positive, says Deutsche Bank
Deutsche Bank analyst Navin Jacob views the initiation of the Reverse NASH trial is a positive for Intercept Pharmaceuticals, saying it "puts to rest any lingering bear arguments that OCA is not safe." The trial, if successful, presents potential upside to numbers, Jacob tells investors in a research note. He keeps a Buy rating on the shares with a $103 price target.
02/07/18
GSCO
02/07/18
DOWNGRADE
Target $45
GSCO
Sell
Intercept downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals to Sell and cut his price target for the shares to $45 from $74. The analyst sees a lack of catalyats to move the stock higher. Intercept closed yesterday up $2.08 to $60.82.
ALXN Alexion
$111.38

0.09 (0.08%)

04/11/18
JEFF
04/11/18
NO CHANGE
Target $113
JEFF
Hold
Market opportunity for Alexion acquired WTX101 likely limited, says Jefferies
After Alexion announced a deal to buy Wilson Therapeutics for $855M, and thus acquire WTX101, a drug in Phase 3 testing for the orphan condition of Wilson disease, Jefferies analyst Eun Yang said she sees the market opportunity for WTX101 as likely limited unless it shows clear superiority versus the current standard of care. She estimates a fair value of $1 per share for WTX101 and raised her price target on Alexion to $113 from $112 to reflect that estimate. Yang keeps a Hold rating on Alexion.
03/28/18
JPMS
03/28/18
NO CHANGE
JPMS
Overweight
Alexion shares 'significantly undervalued' after pullback, says JPMorgan
JPMorgan analyst Anupam Rama says shares of Alexion Pharmaceuticals are "significantly undervalued" after pulling back 15% since the Phase 3 study data release of ALXN1210 in paroxysmal nocturnal hemoglobinuria naive patients. The analyst sees 50%-60% fundamental upside from current levels and keeps an Overweight rating on the shares.
04/12/18
NOMU
04/12/18
NO CHANGE
Target $165
NOMU
Buy
Alexion price target raised to $165 from $156 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Alexion Pharmaceuticals to $165 following the company's acquisition of Wilson Therapeutics. The analyst incorporated WTX101 estimates into his model and keeps a Buy rating on Alexion.
04/11/18
PIPR
04/11/18
NO CHANGE
Target $170
PIPR
Overweight
Alexion acquisition of Wilson 'makes a lot of sense,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond analyst believes Alexion Pharmaceuticals' acquisition of Wilson Therapeutics "makes a lot of sense." The deal adds an incremental value of $4 per share, according to Raymond's model. The analyst say Wilson's WTX101, an oral, high affinity copper binding agent in a Phase 3 trial for the treatment of Wilson's disease, meets a significant unmet need despite two approved, but marginally effective therapies. More strategically, investors will like the evidence of deal execution from the new management team, Raymond tells investors in a research note. He thinks Alexion shares "are well positioned for recovery" and keeps an Overweight rating on the name with a $170 price target.
BAX Baxter
$65.72

-0.05 (-0.08%)

02/20/18
DBAB
02/20/18
UPGRADE
Target $80
DBAB
Buy
Baxter upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Kristen Stewart upgraded Baxter International to Buy and raised her price target for the shares to $80 from $50. The analyst expects management to execute well and she views the company's 2018 guidance as achievable, if not conservative. She sees the May analyst day as an upcoming catalyst and believes the stock deserves a premium valuation.
01/03/18
EVER
01/03/18
INITIATION
Target $71
EVER
Outperform
Baxter initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar started Baxter with an Outperform rating and $71 price target. The analyst thinks Baxter should be able to meet or beat 2018 Street expectations and its balance sheet strength gives it over $10B in capacity for M&A, he tells investors.
01/03/18
RAJA
01/03/18
UPGRADE
Target $73
RAJA
Outperform
Baxter upgraded to Outperform, view as a core holding at Raymond James
Raymond James analyst Lawrence Keusch upgraded Baxter to Outperform from Market Perform and established a $73 price target saying he views it as a core holding. Keusch has high confidence in management execution, an emerging new product portfolio, and balance sheet optionality. He sees organic cc revenue growth in the 4% range driven by geographic expansion after recent underperformance in Europe, as well as continued growth in Asia. Further, after a period of underinvestment, the R&D pipeline as been revitalized and should begin to accelerate growth in 2019 and beyond. Finally, the analyst said Baxter has considerable balance sheet flexibility with $7-$8B available for bolt-on acquisitions.
02/02/18
COWN
02/02/18
NO CHANGE
Target $78
COWN
Market Perform
Baxter guidance reaction unwarranted, says Cowen
Cowen analyst Joshua Jennings noted Baxter's Q2 guidance implied a headwind to operating margins and the shares sold off. The analyst believes the selloff was an overreaction and unwarranted, though, as he believes the guidance could be conservative and it will not disrupt the company's multiyear margin progress. Jennings maintained his Market Perform rating and raised his price target to $78 from $68 on Baxter shares.
GOLD Randgold
$82.26

1.49 (1.84%)

04/04/18
RBCM
04/04/18
DOWNGRADE
RBCM
Underperform
Randgold downgraded to Underperform from Sector Perform at RBC Capital
RBC Capital analyst Tyler Broda downgraded Randgold to Underperform from Sector Perform and lowered his price target to GBp4,900 from GBp6,200. Broda notes that while Randgold has some positives such as a strong balance sheet, a high dividend and a disciplined track record on acquisitions, its attributable production has reached peak levels as its Tongon site is reaching the end of its life and growth from Massawa is uncertain. The analyst further attributes his rating revision to enhanced operating risks in Africa and the uncertainty around the cash flows from the Kibali mine in the Congo.
03/26/18
GSCO
03/26/18
UPGRADE
GSCO
Buy
Randgold upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Eugene King upgraded Randgold Resources while lowering his price target for the shares to 7,500p from 8,000p. The analyst sees an attractive entry point following the stock's recent selloff. He notes that Goldman's commodities team is bullish on gold for the first time in more than five years based on higher inflation, rising emerging market wealth and concerns about an equity correction. King upgraded his sector view to Attractive citing his firm's bullish gold outlook.
02/08/18
HSBC
02/08/18
UPGRADE
HSBC
Buy
Randgold upgraded to Buy from Hold at HSBC
03/13/18
ADAM
03/13/18
UPGRADE
ADAM
Buy
Randgold upgraded to Buy from Hold at Canaccord
Canaccord Genuity analyst Tim Huff upgraded Randgold Resources to Buy while lowering his price target for the shares to GBP 70 from GBP 75. The analyst "conservatively" forecasts an 8% rise in EBITDA through 2020 due to lower cost guidance from management by mine. The analyst views the recent pullback in the shares as a good buying opportunity.
BRG Bluerock Residential
$8.72

0.08 (0.93%)

08/07/17
COMP
08/07/17
DOWNGRADE
COMP
Neutral
Bluerock Residential downgraded to Neutral from Buy at Compass Point
08/07/17
COMP
08/07/17
DOWNGRADE
COMP
Neutral
Follow-up: Bluerock Residential downgraded, dividend cut coming, says Compass
As previously reported, Compass Point downgraded Bluerock Residential to Neutral from Buy and cut its price target to $11 from $16.50. Analyst Steve Shaw said the company said it is reviewing its dividend policy and believes a 50% cut could be coming, and potentially more, and believes it could be a long road back to gain investors' confidence.
12/12/17
JANY
12/12/17
DOWNGRADE
JANY
Neutral
Bluerock Residential downgraded to Neutral from Buy at Janney Capital
02/20/18
NATL
02/20/18
UPGRADE
NATL
Buy
Bluerock Residential upgraded to Buy from Neutral at National Securities
CANF Can-Fite BioPharma
$1.45

(0.00%)

03/12/18
MAXM
03/12/18
DOWNGRADE
MAXM
Hold
Can-Fite BioPharma downgraded to Hold from Buy at Maxim
03/12/18
MAXM
03/12/18
DOWNGRADE
MAXM
Hold
Can-Fite BioPharma downgraded to Hold from Buy at Maxim
Maxim analyst Jason Kolbert downgraded Can-Fite BioPharma to Hold from Buy, saying the company's latest move to raise equity is no longer justifiable of a Buy rating. Kolbert notes that the equity dilution as part of the capital raise was unexpected, adding that the potential impact of raising "too little" capital may also result in more dilution down the line. The analyst also states that his concerns are hightened by limited near term catalysts as well as the expectations of operating capital burn rate of $21M this year against the company's estimated cash balance of $8M-$10M.
08/11/17
MAXM
08/11/17
INITIATION
Target $7
MAXM
Buy
Can-Fite BioPharma initiated with a Buy at Maxim
Maxim analyst Jason McCarthy started Can-Fite Biopharma with a Buy rating, stating that the company has multiple shots on goal in "blockbuster-sized indications" with its A3AR targeting drug piclidenoson. The analyst, who models piclidenoson commercialization in rheumatoid arthritis in 2022 followed by psoriasis in 2023, set a $7 price target on Can-Fite shares.
SBPH Spring Bank Pharmaceuticals
$13.99

0.02 (0.14%)

07/20/17
07/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Neutral at Citi. 2. Johnson & Johnson (JNJ) reinstated with an Outperform at Credit Suisse. 3. Tile Shop (TTS) initiated with a Hold at Loop Capital. 4. Spring Bank Pharmaceuticals (SBPH) initiated with an Overweight at Cantor. 5. Discovery (DISCA) and Scripps Networks (SNI) were initiated with a Market Perform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/19/17
CANT
07/19/17
INITIATION
Target $29
CANT
Overweight
Spring Bank Pharmaceuticals initiated with an Overweight at Cantor
Cantor initiated Spring Bank Pharmaceuticals with an Overweight and a $29 price target.
02/21/18
RILY
02/21/18
NO CHANGE
Target $30
RILY
Buy
Spring Bank remains undervalued hepatitis B play, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar reiterates a Buy rating on Spring Bank Pharmaceuticals with a $30 price target following the company's Q4 results. The analyst says the company remains an undervalued mid-stage hepatitis B therapy play.
11/06/17
RILY
11/06/17
INITIATION
RILY
Buy
Spring Bank Pharmaceuticals initiated with a Buy at B. Riley FBR
MNOV MediciNova
$12.57

-0.66 (-4.99%)

03/28/18
RILY
03/28/18
INITIATION
Target $22
RILY
Buy
MediciNova initiated with a Buy at B. Riley FBR
B. Riley FBR analyst David Buck started MediciNova with a Buy rating and $22 price target.
04/18/17
FBCO
04/18/17
INITIATION
FBCO
Outperform
MediciNova initiated with an Outperform at Credit Suisse
Credit Suisse analyst Dr Yen Tin Chen initiated MediciNova with an Outperform citing its pipeline of small molecules for neurological and fibrotic diseases with high unmet needs and expects the company to turn profitable from FY12/23.
ENTA Enanta
$85.98

1.24 (1.46%)

02/08/18
RBCM
02/08/18
NO CHANGE
Target $78
RBCM
Sector Perform
Enanta price target raised to $78 from $59 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Enanta to $78 after the company's Q1 earnings beat, noting the "high royalties stemming from the Mavyret launch" highlighting Enanta's Hep-C competitive strength. Abrahams keeps his Sector Perform rating, adding that the "potentially de-risking data from '305 in NASH/PBC or '938 in RSV is likely at least a year away".
02/08/18
JPMS
02/08/18
DOWNGRADE
Target $95
JPMS
Neutral
Enanta downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jessica Fye downgraded Enanta Pharmaceuticals to Neutral while raising her price target for the shares to $95 from $55. The analyst believes improved hepatitis C virus royalties and a lower U.S. tax rate are now reflected in the shares. She believes further upside will need to be driven by pipeline progress.
01/02/18
RBCM
01/02/18
DOWNGRADE
RBCM
Sector Perform
Enanta downgraded to Sector Perform at RBC Capital after 'considerable run'
As reported earlier, RBC Capital analyst Brian Abrahams downgraded Enanta (ENTA) to Sector Perform from Outperform, saying his positive near-term thesis on Mavyret has now played out and the potential for long-term royalties from AbbVie (ABBV) are "baked into the stock". The analyst believes that the trajectory of the treatment is now better appreciated" by the Street, adding the stock is more likely to trade in line in the immediate term given the "limited patient data for the NASH/PBC and RSV programs in 2018".
02/08/18
02/08/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Clorox (CLX) downgraded to Hold from Buy at Argus with analyst John Staszak saying that while the company is benefiting from low-cost operations and strong market share, margin pressure and private-label competition pose obstacles to its growth. 2. Cosan (CZZ) downgraded to Neutral from Buy at UBS. 3. Inphi (IPHI) downgraded to Underperform from Neutral at BofA/Merrill with analyst Vivek Arya citing "materially worse" first quarter guidance led by persistent inventory issues in the coherent transimpedance amplifier/driver business in China. 4. Enanta (ENTA) downgraded to Neutral from Overweight at JPMorgan with analyst Jessica Fye saying she believes improved hepatitis C virus royalties and a lower U.S. tax rate are now reflected in the shares. 5. Allison Transmission (ALSN) downgraded to Neutral from Buy at BofA/Merrill with analyst Ross Gilardi saying he expects a strong fourth quarter driven by robust growth in its high margin spare parts business and a recovery in its Off-Highway segment but sees some risks to operating leverage next year due to business mix and higher R&D. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ABUS Arbutus Biopharma
$5.20

0.1 (1.96%)

03/19/18
CHDN
03/19/18
INITIATION
Target $8.25
CHDN
Buy
Arbutus Biopharma reinitiated with a Buy at Chardan
Chardan analyst Gbola Amusa resumed coverage on Arbutus Biopharma with a Buy and $8.25 price target.
03/19/18
WEDB
03/19/18
DOWNGRADE
WEDB
Neutral
Arbutus Biopharma downgraded to Neutral from Outperform at Wedbush
03/19/18
03/19/18
DOWNGRADE
Target $6

Neutral
Arbutus Biopharma downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst Robert Driscoll downgraded Arbutus Biopharma to Neutral from Outperform as he sees limited upside to shares ahead of a lack of meaningful catalysts over the next 12 months. The analyst also lowered his price target on the shares to $6 from $9.
01/05/18
RILY
01/05/18
INITIATION
Target $10
RILY
Buy
Arbutus Biopharma initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Arbutus Biopharma with a Buy rating and $10 price target.
CTRV ContraVir Pharmaceuticals
$0.30

0.0197 (7.03%)

02/13/18
02/13/18
DOWNGRADE

Hold
ContraVir Pharmaceuticals downgraded to Hold at Maxim
As previously reported, Maxim analyst Jason Kolbert downgraded ContraVir Pharmaceuticals to Hold from Buy after the company announced that the FDA agrees the 505b pathway is valid for TXL and as he believes the company will need to raise capital soon. The analyst notes that his fundamental positive outlook on TXL has not changed, however balance sheet concerns represent a key risk to the ContraVir story.
02/13/18
MAXM
02/13/18
DOWNGRADE
MAXM
Hold
ContraVir Pharmaceuticals downgraded to Hold from Buy at Maxim
GALT Galectin Therapeutics
$3.95

-0.32 (-7.49%)

12/07/17
ROTH
12/07/17
NO CHANGE
Target $3
ROTH
Buy
Galectin Therapeutics price target lowered to $3 from $10 at Roth Capital
Roth Capital analyst Yasmeen Rahimi lowered her price target for Galectin Therapeutics to $3 from $10 after the company announced that its Phase 2b NASHCX trial in 161 cirrhotic NASH patients missed its primary endpoint. However, the analyst still sees a few positive points such as clean safety, and reiterates a Buy rating on the shares.
01/04/18
ROTH
01/04/18
NO CHANGE
Target $8
ROTH
Buy
Galectin Therapeutics price target raised to $8 from $3 at Roth Capital
Roth Capital analyst Yasmeen Rahimi raised her price target for Galectin Therapeutics to $8 from $3 after the company announced its $10M unsecured line of credit from Richard Uihlein, new director and long-term shareholder, and 1M stock purchase warrants exercisable at $5/share. The analyst believes this was a needed change and the best strategic choice in eliminating financial pressure through 2019, favorably positioning Galectin Therapeutics in potentially securing a lucrative partnership. Rahimi reiterates a Buy rating on the shares.
12/07/17
HCWC
12/07/17
NO CHANGE
Target $10
HCWC
Buy
H.C. Wainwright says market wrong, ups Galectin target to $10
H.C. Wainwright analyst Ed Arce raised his price target for Galectin Therapeutics to $10 from $6 saying the market got wrong, "again," the company's Phase 2b NASH-CX trial results, which featured a miss on the overall primary efficacy endpoint. The corresponding stock selloff reflects the "inability of many biotech investors to recognize any value from a trial result that does not myopically present as a 'clean in,'" Arce tells investors in a research note. He believes the study is a "landmark" for the treatment of cirrhosis, "not only because it appears to offer the first ever pharmacological benefit in NASH cirrhosis (across several parameters), but also because it defines a highly clinically significant and easily identifiable patient sub-population for treatment: cirrhotics with mild portal hypertension." The analyst sees multiple paths available to Galectin for a registrational Phase 3 program and he reaffirms his Buy rating on the shares.
11/28/17
HCWC
11/28/17
NO CHANGE
Target $6
HCWC
Buy
Galectin Therapeutics price target raised to $6 from $3.50 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Galectin Therapeutics to $6 ahead of the Phase 2b NASH-CX trial readout, which he expects next week. With few therapeutic options in development for the most severely afflicted nonalcoholic steatohepatitis patients, the approvability bar is fairly low, Arce tells investors in a research note. He keeps a Buy rating on Galectin ahead of the NASH-CX readout.
NVO Novo Nordisk
$49.15

-0.82 (-1.64%)

01/22/18
FBCO
01/22/18
DOWNGRADE
Target $82
FBCO
Underperform
Credit Suisse downgrades Lilly to Underperform on mid-term guidance concerns
Credit Suisse analyst Vamil Divan downgraded Eli Lilly (LLY) to Underperform from Neutral and cut his price target for the shares to $82 from $88. The analyst does not believe Lilly is on track to hit its mid-term guidance of 5% annual sales growth from 2015-2020. Divan notes he's $500M below consensus for Trulicity in 2021 based on market share gains for Novo Nordisk's (NVO) Victoza following its recent label expansion, the threat from Novo's once-weekly Ozempic and risk from upcoming Phase 3 data for Novo's oral semaglutide. Trulicity accounts for 40% of Lilly's sales growth from 2016-2021 based on current expectations, Divan tells investors in a research note partially titled "Diabetes Challenges Leave Sour Taste in Our Mouth"
02/26/18
JPMS
02/26/18
NO CHANGE
Target $105
JPMS
Overweight
Concerns over Eli Lilly diabetes franchise overdone, says JPMorgan
JPMorgan analyst Chris Schott believes longer-term growth concerns surrounding Trulicity and Eli Lilly's (LLY) broader diabetes franchise are overdone following Novo Nordisk's (NVO) oral semaglutide results as well as the launch of Ozempic. The analyst sees a buying opportunity in shares of Eli Lilly following the recent pullback. Lilly is a "highly diversified growth story" and competition to Trulicity is manageable, Schott tells investors in a research note. He keeps an Overweight rating on the shares with a $105 price target.
01/19/18
GSCO
01/19/18
UPGRADE
GSCO
Conviction Buy
Novo Nordisk upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Keyur Parekh reiterates a Buy rating on Novo Nordisk and added the stock to the firm's Conviction List, as he sees the company's GLP-1 franchise setting it up for a new period of high compounding revenue and EPS growth after 2018. Following a deep-dive on Ozempic and oral semaglutide, he raised his 2020-22 revenue estimates by 3%-6% and his EPS estimates in the period by 5%-10%. Parekh also raised his price target on Novo Nordisk shares to DKK450 from DKK345.
04/05/18
RHCO
04/05/18
NO CHANGE
Target $101
RHCO
Buy
Eli Lilly supported by positive oncology and diabetes findings, says SunTrust
SunTrust analyst John Boris keeps his Buy rating and $101 price target on Eli Lilly (LLY), citing the latest developments in Oncology and Diabetes. In Oncology, Boris points to the positive Overall Survival and Progression Free Survival data for Cyramza in second-line hepatocellular carcinoma, though he sees the commercial opportunity in Hepatocellular Carcinoma as limited. In Diabetes, the analyst points to the latest data showing Trulicity gaining market share on Novo Nordisk's (NVO) Victoza in the GLP-1 market.
OSUR OraSure
$16.80

-0.27 (-1.58%)

11/02/17
JEFF
11/02/17
DOWNGRADE
Target $17
JEFF
Hold
OraSure downgraded to Hold from Buy at Jefferies
Jefferies analyst Brandon Couillard downgraded OraSure to Hold saying the "abrupt" early termination of the company's first major international hepatitis C virus government eradication contract diminishes the outlook. He believes the contract was with Egypt. Competitive displacement from low-cost lab options is a new concern, Couillard tells investors in a post-earnings research note. He cut his price target for OraSure shares to $17 from $23.
11/22/17
ADAM
11/22/17
NO CHANGE
Target $21
ADAM
Buy
OraSure contract win bigger than full year revenues, says Canaccord
Canaccord analyst Mark Massaro noted OraSure won a massive $143M contract to supply its market-leading Oragene Dx saliva collection device to a leading generics customer. The analyst said the contract win is bigger than its previous year revenue number and indicates the direct-to-consumer genomics business is booming. Massaro reiterated his Buy rating and raised his price target to $21 from $19 on OraSure shares.
11/21/17
KING
11/21/17
NO CHANGE
Target $19
KING
Buy
OraSure signs $143M deal, likely with 23andMe, says CL King
OraSure announced it signed a $143M deal with a consumer genomics company. CL King analyst David Westenberg believes the company is likely 23andme and views it as a positive as it indicates the initial $20M deal its signed with the company in April has been fulfilled significantly earlier than expected. The analyst believes Orasure's exposure to the consumer genomics market provides significant upside to estimates. Westenberg rates OraSure a Buy with a $19 price target.
11/22/17
JEFF
11/22/17
NO CHANGE
JEFF
Hold
Jefferies unclear how much of 'eye-catching' OraSure contract is incremental
Jefferies analyst Brandon Couillard said the size of the $143M contract announced by OraSure was "eye-catching," but that it is still unclear how much of this is truly incremental to the current run-rate with the customer in question. The analyst, who said his "best guess" and current assumption is that the contract is with 23&Me, maintains a Hold rating on OraSure shares.
ONVO Organovo
$1.01

-0.04 (-3.81%)

11/10/17
RAJA
11/10/17
DOWNGRADE
RAJA
Market Perform
Organovo downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Reni Benjamin downgraded Organovo to Market Perform citing management's lowering of 2018 revenue guidance and uncertainty the company's disease modeling business. The analyst removed his price target for the shares.
SIEGY Siemens
$64.65

-0.015 (-0.02%)

12/05/17
LEHM
12/05/17
DOWNGRADE
LEHM
Underweight
Siemens downgraded to Underweight from Equal Weight at Barclays
Barclays analyst James Stettler downgraded Siemens to Underweight and lowered his price target for the shares to EUR 110 from EUR 125.
04/02/18
VERT
04/02/18
UPGRADE
VERT
Buy
Siemens upgraded to Buy from Hold at Vertical Research
12/11/17
MSCO
12/11/17
UPGRADE
MSCO
Overweight
Siemens upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Ben Uglow upgraded Siemens to Overweight with a price target of EUR 134.
10/25/17
RBCM
10/25/17
UPGRADE
Target $100
RBCM
Top Pick
Synopsys upgraded to Top Pick on IoT and AI exposure at RBC Capital
As previously noted, RBC Capital analyst Mitch Steves upgraded Synopsys to Top Pick from Outperform and raised his price target to $100 from $90. Steves says the company's margin profile should improve over the next 2-3 years given the company's exposure to the "Internet of Things", Artificial Intelligence and Semiconductor content in automobiles. Steves also notes the company has an opportunity to take "sticky" hardware market share from Siemens' (SIEGY) Mentor Graphics.
VTL Vital Therapies
$5.90

0.1 (1.72%)

05/18/17
RAJA
05/18/17
INITIATION
Target $6
RAJA
Outperform
Vital Therapies initiated with an Outperform at Raymond James
Raymond James analyst Laura Chico initiated Vital Therapies with an Outperform and a $6 price target saying the the current pivotal VTL-308 Phase 3 study presents the opportunity to definitively determine if ELAD can improve survival outcomes among patients with acute alcoholic hepatitis and thinks it could be of interest for risk/tolerant investors, assuming approval.
FMS Fresenius Medical
$50.86

-0.01 (-0.02%)

03/29/18
RBCM
03/29/18
NO CHANGE
Target $25
RBCM
Sector Perform
Akorn price target lowered to $25 from $34 at RBC Capital
RBC Capital analyst Randall Stanicky lowered his price target on Akorn (AKRX) to $25 on "probability-adjusted scenario analysis" around the company's ongoing takeover discussions with Fresenius (FMS). Stanicky says that while the closing of the deal is the most likely outcome, there is some uncertainty based on last month's reports of "data integrity breaches" at Akorn. The analyst adds that his calls to Fresenius management have not yielded any updates, keeping his Sector Perform rating on Akorn.
01/04/18
UBSW
01/04/18
UPGRADE
UBSW
Neutral
Fresenius Medical upgraded to Neutral from Sell at UBS
08/22/17
08/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mylan (MYL) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg citing the cut in 2017 guidance. He said Mylan may also have difficulty improving operations in the near-term due to unfavorable EpiPen regulatory developments, pricing pressures, and increased competition. 2. Brookfield (BIP) downgraded to Neutral from Outperform at Credit Suisse, with analyst Andrew Kuske saying he is exiting his long "tactical trade" given recent outperformance. 3. Global Medical REIT (GMRE) downgraded to Neutral from Buy at DA Davidson with analyst Barry Oxford saying that the stock "could be range bound for a period of time" following the departures of the REIT's CEO and CFO and due to "potential concerns regarding the dividend and acquisitions." 4. NxStage Medical (NXTM) downgraded to Market Perform from Outperform at Leerink, as analyst Danielle Antalffy said it is unlikely another bidder will top Fresenius Medical's (FMS) $30 per share offer for the company. 5. Hikma (HKMPY) downgraded to Neutral from Buy at Goldman Sachs, with analyst Yulia Gerasimova citing Roxane integration issues, delayed generic Advair approval, ongoing U.S. generics pricing erosion, and multiple guidance downgrades from the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/11/17
MSCO
12/11/17
DOWNGRADE
MSCO
Equal Weight
Fresenius Medical downgraded to Equal Weight from Overweight at Morgan Stanley

TODAY'S FREE FLY STORIES

VNQ

Vanguard REIT Index Fund

$77.68

0.64 (0.83%)

14:40
10/23/18
10/23
14:40
10/23/18
14:40
Options
66K Vanguard Real Estate Fund Dec 76 - Jan 72 put spreads trade 71c »

66K Vanguard Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEEV

Veeva

$88.99

-2.77 (-3.02%)

14:35
10/23/18
10/23
14:35
10/23/18
14:35
Options
Veeva put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
10/23/18
10/23
14:35
10/23/18
14:35
General news
Fed Board minutes showed showed most Banks supported the September 26 rate hike »

Fed Board minutes showed…

TSLA

Tesla

$292.00

30.97 (11.86%)

14:32
10/23/18
10/23
14:32
10/23/18
14:32
Recommendations
Tesla analyst commentary  »

Tesla's moved up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 13

    Dec

TTWO

Take-Two

$118.82

-1.69 (-1.40%)

14:30
10/23/18
10/23
14:30
10/23/18
14:30
Periodicals
'Red Dead Redemption 2' development a difficult experience, Kotaku says »

Take-Two's Rockstar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

SELB

Selecta Biosciences

$9.25

-4.12 (-30.82%)

, HZNP

Horizon Pharma

$18.49

-0.76 (-3.95%)

14:29
10/23/18
10/23
14:29
10/23/18
14:29
Recommendations
Selecta Biosciences, Horizon Pharma analyst commentary  »

Selecta SEL-212 data…

SELB

Selecta Biosciences

$9.25

-4.12 (-30.82%)

HZNP

Horizon Pharma

$18.49

-0.76 (-3.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 07

    Nov

  • 27

    Nov

BCS

Barclays

$8.60

0.11 (1.30%)

14:20
10/23/18
10/23
14:20
10/23/18
14:20
Options
8-strike put buyers in Barclays Bank ahead of earnings »

8-strike put buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SELB

Selecta Biosciences

$8.93

-4.44 (-33.21%)

14:19
10/23/18
10/23
14:19
10/23/18
14:19
Recommendations
Selecta Biosciences analyst commentary  »

Selecta Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SLG

SL Green Realty

$92.15

0.36 (0.39%)

14:18
10/23/18
10/23
14:18
10/23/18
14:18
Downgrade
SL Green Realty rating change  »

SL Green Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/23/18
10/23
14:17
10/23/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$133.39

-7.945 (-5.62%)

14:16
10/23/18
10/23
14:16
10/23/18
14:16
Recommendations
Centene analyst commentary  »

Centene should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 14

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/23/18
10/23
14:16
10/23/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$22.65

-1.255 (-5.25%)

14:15
10/23/18
10/23
14:15
10/23/18
14:15
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

SBH

Sally Beauty

$17.78

0.28 (1.60%)

14:09
10/23/18
10/23
14:09
10/23/18
14:09
Hot Stocks
Sally Beauty unveils Sally Beauty Rewards »

"Sally Beauty …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICAD

iCAD

$3.10

-0.02 (-0.64%)

14:06
10/23/18
10/23
14:06
10/23/18
14:06
Hot Stocks
iCAD announces new clinical data on the Xoft Electronic Brachytherapy System »

iCAD announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

AMD

AMD

$24.73

-0.31 (-1.24%)

14:05
10/23/18
10/23
14:05
10/23/18
14:05
Hot Stocks
AMD, Oracle collaborate on EPYC processor-based offering »

At Oracle's (ORCL)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Dec

UNH

UnitedHealth

$261.89

-0.26 (-0.10%)

14:05
10/23/18
10/23
14:05
10/23/18
14:05
Options
UnitedHealth call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$152.62

-2.19 (-1.41%)

14:03
10/23/18
10/23
14:03
10/23/18
14:03
Hot Stocks
Facebook introduces Messenger 4 »

In a blog posting,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

14:00
10/23/18
10/23
14:00
10/23/18
14:00
General news
Breaking General news story  »

Dallas Federal Reserve…

KR

Kroger

$28.16

0.17 (0.61%)

13:58
10/23/18
10/23
13:58
10/23/18
13:58
Hot Stocks
Kroger hiring 10,000 associates for holiday season »

The Kroger Co. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

EXAS

Exact Sciences

$63.00

0.68 (1.09%)

13:55
10/23/18
10/23
13:55
10/23/18
13:55
Periodicals
Exact Sciences named a core healthcare short at Hedgeye »

Hedgeye named Exact…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

EOG

EOG Resources

$110.23

-6.03 (-5.19%)

13:55
10/23/18
10/23
13:55
10/23/18
13:55
Options
EOG Resources put volume heavy and directionally bearish »

Bearish flow noted in EOG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

SELB

Selecta Biosciences

$9.06

-4.31 (-32.24%)

, HZNP

Horizon Pharma

$18.52

-0.735 (-3.82%)

13:53
10/23/18
10/23
13:53
10/23/18
13:53
Hot Stocks
Street Fight: Analysts diverge on Selecta Bio's gout drug data read-through »

Shares of Selecta…

SELB

Selecta Biosciences

$9.06

-4.31 (-32.24%)

HZNP

Horizon Pharma

$18.52

-0.735 (-3.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 07

    Nov

  • 27

    Nov

13:50
10/23/18
10/23
13:50
10/23/18
13:50
General news
Fed's Bostic continues to tout a gradual path of tightening »

Fed's Bostic…

UNP

Union Pacific

$143.76

-3.04 (-2.07%)

13:47
10/23/18
10/23
13:47
10/23/18
13:47
Periodicals
Union Pacific eliminating 475 positions by year end, World-Herald says »

Union Pacific said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.